PROTAC GSK-3β Degrader-1

PROTAC GSK-3β Degrader-1

• UNSPSC Description: PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets GSK-3β degradation with an IC50 value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ25-35 peptide and CuSO4. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease[1].
• Target Antigen: GSK-3; PROTACs
• Type: Reference compound
• Related Pathways: PI3K/Akt/mTOR;PROTAC;Stem Cell/Wnt
• Applications: Neuroscience-Neurodegeneration
• Field of Research: Neurological Disease
• Assay Protocol: https://www.medchemexpress.com/protac-gsk-3β-degrader-1.html
• Solubility: 10 mM in DMSO
• Smiles: ClC1=CC(Cl)=CC=C1C(C(NC2=O)=O)=C2C3=CN(C4=CC=CC=C34)CC(NCCCOCCCCOCCCNC5=C(C6=CC=C5)C(N(C6=O)C7CCC(NC7=O)=O)=O)=O
• Molecular Weight: 857.73
• References & Citations: [1]Guardigni M, et al. PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer's Disease. ACS Chem Neurosci. 2023 Jun 7;14(11):1963-1970.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported